Marshall Wace
STLN

Marshall Wace’s Starling Oncology STLN Stock Holding History

Marshall Wace’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.64M Buy
1,222,498
+880,233
+257% +$3.7M 0.01% 1229
2026
Q1 		$1.05M Buy
342,265
+161,965
+90% +$497K ﹤0.01% 2114
2025
Q4 		$642K Buy
180,300
+155,136
+616% +$575K ﹤0.01% 2140
2025
Q3 		$87.8K Sell
25,164
-1,451,782
-98% -$4.97M ﹤0.01% 2672
2025
Q2 		$3.03M Buy
+1,476,946
New +$3.69M ﹤0.01% 1373
2024
Q1 		– Sell
-39,282
Closed -$80.1K – 2803
2023
Q4 		$80.1K Buy
+39,282
New +$68.1K ﹤0.01% 2057
2021
Q4 		– Sell
-252,439
Closed -$2.5M – 4280
2021
Q3 		$2.5M Buy
252,439
+1,400
+0.6% +$13.9K 0.01% 1388
2021
Q2 		$2.5M Hold
251,039
– – 0.01% 1269
2021
Q1 		$2.5M Buy
251,039
+1,071
+0.4% +$11.4K 0.01% 1203
2020
Q4 		$2.7M Hold
249,968
– – 0.01% 818
2020
Q3 		$2.59M Buy
+249,968
New +$2.6M 0.02% 738

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Marshall Wace's STLN Position: Q2 2026 in Review

Marshall Wace increased its Starling Oncology (STLN) stake by 257% in Q2 2026, buying an estimated $3.7M and bringing the position to 1,222,498 shares worth $6.64M. The position accounts for 0.01% of the portfolio, ranked #1229.

Marshall Wace first reported a position in STLN in Q3 2020 and has held it in 11 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Marshall Wace held 1,222,498 shares of Starling Oncology worth $6.64M as of Q2 2026.
  • Marshall Wace bought 880,233 Starling Oncology shares in Q2 2026, an estimated $3.7M.
  • Starling Oncology made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #1229 holding.
  • Marshall Wace first reported a position in Starling Oncology in Q3 2020 and has held it in 11 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.